The identification of HER2 low cancers as a distinct therapeutic target has fundamentally altered the oncology treatment landscape. This breakthrough recognition has unleashed a wave of innovation and investment, creating new hope for patients and substantial commercial opportunities for pharmaceutical companies committed to advancing precision medicine. The Science Behind HER2 Low Cancer Recognition HER2 low… Read.